#Vienna #Austria #RNA Sequencing #Lexogen #Ochre Bio

Lexogen and Ochre Bio Team Up for Pioneering RNA Sequencing Project

On November 25, 2025, Lexogen, a biotechnology company based in Vienna, unveiled the successful completion of a large-scale next-generation sequencing (NGS) project in collaboration with Ochre Bio. This innovative initiative aimed to create comprehensive data sets for functional genomics derived from human primary hepatocytes. The project marked a significant milestone in the realm of RNA transcriptomics, employing Lexogen's proprietary high-resolution gene expression profiling technology without the need for extraction.

Project Highlights

The project involved the analysis of over 120,000 samples, showcasing the capabilities of Lexogen's advanced sequencing services. Ochre Bio, known for its focus on RNA therapies for chronic liver diseases, has leveraged extensive human liver data to enhance the understanding of genetic disruptions and diseases. With the help of advanced analytical software like OBELiX, Ochre Bio can effectively prioritize targets for therapeutic development based on the underlying biology revealed through the data.

Quin Wills, the founder and CEO of Ochre Bio, emphasized the importance of robust data quality in the field of AI-driven target discovery. He explained, "The power of a platform hinges on the data that fuels it. With a complex system like human primary hepatocytes, rigorous data quality and consistency are vital for interpretability. High-precision sequencing data enables machine-learning models to filter biological signals from technical noise."

The Role of Lexogen NGS Services

Lexogen has established itself as a long-term sequencing partner for Ochre Bio, committed to delivering high-quality RNA sequencing data from a diverse range of samples, including FFPE samples, microorganisms, and primary hepatocytes at scale. Lexogen's NGS services operate in accordance with Good Laboratory Practices (GLP) and employ advanced technologies designed to meet strict ISO 13485 standards. With a dedicated team of experts, Lexogen offers streamlined and customizable workflows to ensure optimal results for even the most challenging samples.

Whether it's the proprietary THOR technology that allows for RNA sequencing without extraction or the expertise behind the RNA-Seq service, Lexogen's contributions have enabled robust, large-scale data generation that lays the groundwork for enhanced target predictions in the future.

Stephane Barges, CEO of Lexogen, expressed pride in the team's commitment to quality. He stated, "Our mission goes beyond providing high-quality services at scale; it's about empowering researchers and companies to advance their discoveries while improving patient lives. We are grateful that our work plays a role—however small—in enhancing health for everyone."

About Lexogen

For nearly two decades, Lexogen has been dedicated to providing comprehensive solutions for transcriptomic analysis and RNA sequencing. Their diverse product line includes kits, reagents, bioinformatics tools, and contract research organization (CRO) services. Manufactured in Vienna, Austria, Lexogen's products adhere to the highest quality standards, certified by ISO 9001 and ISO 1385, and are executed in compliance with GLP and GDPR regulations.
For more information, visit Lexogen's website and follow them on social media for updates.